BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Agreement on Molecular Design of Small Molecule Protein-Protein Interaction (PPI) Inhibitor Between Interprotein and Takeda Pharmaceutical Co. Ltd. (TKPYY)


4/19/2013 10:42:56 AM

April, 2013 -- Interprotein Corporation (President, Masato HOSODA; Headquarters: Osaka, Japan; hereinafter “Interprotein”) today announced that Interprotein and Takeda Pharmaceutical Company Limited (Headquarters: Osaka, Japan; hereinafter “Takeda”) have entered into an agreement on the molecular design of small molecule PPI inhibitors using INTENDD (INTerprotein’s ENgine for New Drug Design), a platform technology of Interprotein. Interprotein announced on December 27, 2011 that Interprotein and Takeda entered into a prior agreement on molecular design of small molecule PPI inhibitors (News Release only in Japanese), and also on November 22, 2012, that a desirable result was obtained through an examination under the agreement. The present agreement, whose theme is different from the prior one, was signed based on the result of this examination. Interprotein will conduct molecular design in terms of a PPI target proposed by Takeda under the present agreement, and Takeda will conduct drug discovery research based on the design.

Contact:

Hirotsugu KOMATSU, Ph.D.

Interprotein Corporation

TEL/FAX: +81-(0)42-770-9477

E-mail:info@interprotein.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->